Lipoprotein (a) and incident coronary heart disease in the community: impact of traditional cardiovascular risk factors - Summary - MDSpire

Lipoprotein (a) and incident coronary heart disease in the community: impact of traditional cardiovascular risk factors

  • By

  • Natalie Arnold

  • Alina Goßling

  • Benjamin Bay

  • Jessica Weimann

  • Christopher Blaum

  • Fabian J Brunner

  • Marco M Ferrario

  • Paolo Brambilla

  • Giancarlo Cesana

  • Valerio Leoni

  • Luigi Palmieri

  • Chiara Donfrancesco

  • Teresa Padró

  • Jonas Andersson

  • Pekka Jousilahti

  • Francisco Ojeda

  • Tanja Zeller

  • Allan Linneberg

  • Stefan Söderberg

  • Licia Iacoviello

  • Francesco Gianfagna

  • Susana Sans

  • Giovanni Veronesi

  • Barbara Thorand

  • Annette Peters

  • Hugh Tunstall-Pedoe

  • Frank Kee

  • Veikko Salomaa

  • Renate B Schnabel

  • Kari Kuulasmaa

  • Stefan Blankenberg

  • Christoph Waldeyer

  • Wolfgang Koenig

  • on behalf of the BiomarCARE investigators

  • June 12, 2025

  • 0 min

Share

Objective:

To investigate the association between high Lipoprotein (a) levels and incident coronary heart disease (CHD) in relation to traditional cardiovascular risk factors (CVRFs) in a general population.

Key Findings:
  • 3467 incident CHD events occurred during a median follow-up of 9.7 years.
  • Increased Lp(a) mass (≥90th percentile) was associated with future CHD events, regardless of baseline CVRF status.
  • The hazard ratios for elevated Lp(a) were 1.38 for individuals with 0/1 CVRFs and 1.27 for those with ≥2 CVRFs.
Interpretation:

High Lp(a) levels are linked to increased CHD risk even in individuals with low traditional CVRFs, indicating challenges in managing Lp(a)-associated risk in low-risk populations.

Limitations:
  • The study is observational and cannot establish causation.
  • Potential confounding factors may not have been fully accounted for.
Conclusion:

There is a significant association between high Lp(a) levels and CHD risk, highlighting the need for targeted therapies for Lp(a) in primary prevention, especially in low-risk individuals.

Original Source(s)

Lipoprotein (a) and incident coronary heart disease in the community: impact of traditional cardiovascular risk factors

  • by Natalie Arnold, Alina Goßling, Benjamin Bay, Jessica Weimann, Christopher Blaum, Fabian J Brunner, Marco M Ferrario, Paolo Brambilla, Giancarlo Cesana, Valerio Leoni, Luigi Palmieri, Chiara Donfrancesco, Teresa Padró, Jonas Andersson, Pekka Jousilahti, Francisco Ojeda, Tanja Zeller, Allan Linneberg, Stefan Söderberg, Licia Iacoviello, Francesco Gianfagna, Susana Sans, Giovanni Veronesi, Barbara Thorand, Annette Peters, Hugh Tunstall-Pedoe, Frank Kee, Veikko Salomaa, Renate B Schnabel, Kari Kuulasmaa, Stefan Blankenberg, Christoph Waldeyer, Wolfgang Koenig, on behalf of the BiomarCARE investigators

  • June 12, 2025

Related Content

Systemic immune-inflammation Index and blood pressure control are independent and interactive predictors of atrial fibrillation recurrence after ablation

Explainable and interpretable models for predicting early-onset hypertension in the Tlalpan 2020 cohort

An epidemiological assessment of the distribution and sociodemographic burden of chronic diseases: a focus on hypertension, diabetes, and cardiovascular conditions